ArQule up on hope for lung cancer drug revival – Reuters

by lowes1 on September 27, 2013

ArQule up on hope for lung cancer drug revival
Reuters
Sept 27 (Reuters) – ArQule Inc shares jumped 19 percent on hopes that additional data from a discontinued trial could revive its experimental drug, tivantinib, as a treatment for lung cancer. Last October, ArQule and Daiichi Sankyo Inc stopped a late
ArQule rises on renewed hope for twice-damned tivantinibFierceBiotech

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: